Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on August 31, 2021. The filing serves as a Regulation FD disclosure and report of other events regarding the status of the Company's pivotal ONWARD Phase 3 clinical trial for its lead drug candidate, AD04, intended for the treatment of Alcohol Use Disorder (AUD).
Key Financial Metrics
This filing is a current report regarding clinical trial progress and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material update concerns the operational status of the ONWARD Phase 3 clinical trial:
- Enrollment Status: Enrollment is officially closed.
- Patient Count: A total of 302 patients have been enrolled.
- Geographic Scope: The trial utilized 25 clinical sites across Scandinavia and Central and Eastern Europe, including Sweden, Finland, Poland, Latvia, Bulgaria, and Croatia.
Guidance, Outlook, and Risks
Outlook and Timeline:
- Patient dosing is expected to be completed in the first quarter of 2022.
- Data readout is anticipated to follow as soon as practical after dosing completion.
Risks and Contingencies:
- The press release referenced in this filing contains "forward-looking" statements subject to risks and uncertainties.
- The Company explicitly states it undertakes no duty or obligation to update or revise the information contained in this report, though it may do so at management's discretion.
Key Facts for Investor Verification
- Verify the exact date of patient dosing completion against the Q1 2022 guidance.
- Confirm the final patient enrollment number (302) and site count (25) in future regulatory updates.
- Monitor for the subsequent data readout announcement following the completion of dosing.
- Note that this filing does not include financial performance data; refer to the most recent 10-Q or 10-K for financial health metrics.